Pharma industry reports 66 deals worth $26.1 billion in December 2021: GlobalData

The pharma industry reported 66 deals worth $26.1 billion as compared to the last 12-month average (December 2020 to November 2021) of 98 deals worth $21.6 billion, GlobalData has said.

In a statement, the company said that CSL to acquire Vifor Pharma for approximately $12.3 billion; Pfizer Inc to acquire Arena Pharmaceuticals Inc for a total equity value of approximately $6.7 billion; and Triton Investment Management through Triley Bidco, to acquire entire issued and to be issued ordinary share capital of Clinigen Group Plc, for a consideration of approximately $1.6 billion were the three major deals that contributed 78.5 per cent of the total deal value during December 2021.

The industry reported 117 venture capital (VC) deals worth $3.8 billion in December 2021, compared to the last 12-month average (December 2020 to November 2021) of 179 deals worth $5.4 billion, the statement added.

It also notified that Odyssey Therapeutics Inc, raising $218 million in series A financing to advance next-generation inflammation and Oncology medicines; Beijing Anshi Biotechnology Company raising $200 million in series A financing; and Avistone Pharmaceuticals raising $200 million in series A financing to support the accelerated development of its existing drug candidate and expand its product pipeline were the major VC deals reported in December 2021.